Status: Recruiting
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
This is a multicenter, single arm, phase II study aimed at evaluating ibrutinib therapy for the treatment of AIHA in patients with CLL/SLL or CLL-like MBL.
Participants needed: 45
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Gruppo Italiano Malattie EMatologiche dell'AdultoUpdated: Dec 1, 2023Locations: 3
Eligibility criteria
Diagnosis of CLL/small lymphocytic lymphoma (SLL) or CLL-like monoclonal B-cell... [+4]
Contraindication to ibrutinib therapy as per treating physician's discretion. [+4]